We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+45.38%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$22.7B
AUM Growth
+$6.43B
Cap. Flow
-$298M
Cap. Flow %
-1.32%
Top 10 Hldgs %
85.22%
Holding
124
New
14
Increased
20
Reduced
17
Closed
10

Top Buys

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$116M
2
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$86.7M
3
ADCT icon
ADC Therapeutics
ADCT
+$64M
4
NVTA
Invitae Corporation
NVTA
+$48M
5
SYRE icon
Spyre Therapeutics
SYRE
+$20.3M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$416M
2
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$101M
3
TCDA
Tricida, Inc. Common Stock
TCDA
+$51.2M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$36.8M
5
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$23.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.74%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KNSA icon
26
Kiniksa Pharmaceuticals
KNSA
$6.23B
$71.3M 0.31%
2,799,577
– –
ADAP
27
DELISTED
Adaptimmune Therapeutics
ADAP
$66.8M 0.29%
6,675,181
+2,984,874
+81% +$18.7M
BCRX icon
28
BioCryst Pharmaceuticals
BCRX
$2.42B
$65.6M 0.29%
13,766,405
+2,820,239
+26% +$11.3M
DBVT
29
DBV Technologies
DBVT
$816M
$64.2M 0.28%
1,461,426
– –
ZYME icon
30
Zymeworks
ZYME
$1.62B
$61.6M 0.27%
1,708,472
– –
RYTM icon
31
Rhythm Pharmaceuticals
RYTM
$7.3B
$60.2M 0.27%
2,700,055
-8,145
-0.3% -$159K
NGNE icon
32
Neurogene
NGNE
$669M
$56.4M 0.25%
169,887
– –
CCXI
33
DELISTED
ChemoCentryx, Inc.
CCXI
$54.4M 0.24%
945,221
+86,206
+10% +$4.69M
ALLK
34
DELISTED
Allakos
ALLK
$52.9M 0.23%
735,469
– –
SYRE icon
35
Spyre Therapeutics
SYRE
$8.5B
$40.5M 0.18%
175,184
+106,640
+156% +$20.3M
ASMB icon
36
Assembly Biosciences
ASMB
$499M
$36M 0.16%
128,468
– –
KRYS icon
37
Krystal Biotech
KRYS
$10.7B
$33.9M 0.15%
817,631
-128,840
-14% -$6.2M
PTGX icon
38
Protagonist Therapeutics
PTGX
$8.55B
$33.8M 0.15%
1,911,446
+232,282
+14% +$2.91M
MRUS
39
DELISTED
Merus
MRUS
$32.8M 0.14%
2,037,469
– –
APLS
40
DELISTED
Apellis Pharmaceuticals
APLS
$29.3M 0.13%
896,551
– –
AUPH icon
41
Aurinia Pharmaceuticals
AUPH
$1.95B
$27.7M 0.12%
1,701,929
– –
ALKS icon
42
Alkermes
ALKS
$8.1B
$24.2M 0.11%
1,244,744
– –
GWPH
43
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$22.7M 0.1%
185,045
-185,800
-50% -$21.1M
ALT icon
44
Altimmune
ALT
$568M
$22.6M 0.1%
+2,107,600
New +$11.6M
ADPT icon
45
Adaptive Biotechnologies
ADPT
$3.61B
$22.4M 0.1%
463,539
-280,195
-38% -$10.2M
KRRO icon
46
Korro Bio
KRRO
$145M
$22M 0.1%
18,914
-4,689
-20% -$4.24M
TCDA
47
DELISTED
Tricida, Inc. Common Stock
TCDA
$21.6M 0.1%
787,582
-1,878,433
-70% -$51.2M
NVAX icon
48
Novavax
NVAX
$1.21B
$20.1M 0.09%
+241,376
New +$9.23M
BLUE
49
DELISTED
bluebird bio
BLUE
$16.2M 0.07%
20,458
+17,370
+563% +$13.1M
VXRT
50
DELISTED
Vaxart
VXRT
$14.5M 0.06%
+1,639,121
New +$4.71M
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2020 Portfolio in Review

As of Q2 2020, Baker Bros. Advisors held 124 positions worth $22.7B, up 40% from $16.2B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Baker Bros. Advisors's Q2 2020 filing shows 14 new, 20 increased, 17 reduced and 10 closed positions. Its largest new stake was Forma Therapeutics Holdings, Inc. Common Stock: 2,000,000 shares worth $93M. The largest sale was Seagen Inc. Common Stock, an estimated $416M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q2 2020 buy was Forma Therapeutics Holdings, Inc. Common Stock: 2,000,000 shares worth $93M.
  • Baker Bros. Advisors added most to MyoKardia, Inc. Common Stock in Q2 2020, an estimated $116M increase.
  • Baker Bros. Advisors's biggest Q2 2020 reduction was Seagen Inc. Common Stock, cutting an estimated $416M.
  • Baker Bros. Advisors fully exited Ra Pharmaceuticals, Inc. Common Stock in Q2 2020, selling an estimated $101M.
  • Baker Bros. Advisors's ten largest holdings make up 85% of its $22.7B portfolio in Q2 2020.
  • Baker Bros. Advisors opened 14 new positions and closed 10 in Q2 2020.
  • Baker Bros. Advisors's portfolio value rose 40% quarter-over-quarter to $22.7B.

Based on Baker Bros. Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.